NCT05243550 2024-11-04ENVISIONUroGen Pharma Ltd.Phase 3 Active not recruiting240 enrolled 20 charts 1 FDA
NCT05136898 2024-09-19Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)UroGen Pharma Ltd.Phase 3 Completed8 enrolled 18 charts
NCT02773849 2024-07-29ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)Ferring PharmaceuticalsPhase 3 Completed157 enrolled 22 charts 1 FDA
NCT02563561 2021-10-27A Study of Intravesical Apaziquone as a Surgical Adjuvant in Participant Undergoing Transurethral Resection Bladder Tumor (TURBT)Spectrum Pharmaceuticals, IncPhase 3 Terminated62 enrolled 10 charts
NCT02560584 2018-07-02A Study of Blue Light Flexible Cystoscopy With Cysview in the Detection of Bladder Cancer in the Surveillance SettingPhotocurePhase 3 Completed304 enrolled 11 charts
NCT01469221 2017-12-15Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)Spectrum Pharmaceuticals, IncPhase 3 Terminated47 enrolled 11 charts
NCT01310803 2017-10-05Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the BladderEndo PharmaceuticalsPhase 3 Terminated1 enrolled 5 charts
NCT01410565 2016-12-13Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder CancerSpectrum Pharmaceuticals, IncPhase 3 Terminated66 enrolled 12 charts